Skip to main content

Find Clinical Trials

Home
Conditions
Mantle Cell Lymphoma

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

251 public trials 59 recruiting studies

Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Recruiting

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

NCT07453095

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: AOU SS. Antonio e Biagio e Cesare Arrigo - SCDU Ematologia Alessandria, Italy

Policlinico S.Orsola-Malpighi - Istituto di Ematologia Seragnoli Bologna, Italy

ASST Spedali Civili - Ematologia Brescia, Italy

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia Florence, Italy

View all 14 locations

View Trial Details

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762

Conditions: Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +36 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184

Conditions: CLL, Chronic Disease, Chronic Lymphocytic Leukemia, +22 more
Locations: Moffitt Cancer Center Tampa, Florida, United States

Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States

The University of Kansas Cancer Center Westwood, Kansas, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

View all 17 locations

View Trial Details

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +59 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

NCT07261163

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China

Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

CD70-targeted immunoPET Imaging of Malignant Cancers

NCT06852638

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +37 more
Locations: Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, China

View Trial Details

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

NCT05887167

Conditions: Acute Lymphoblastic Leukemia, Blood Protein Disorders, Cardiovascular Diseases, +28 more
Locations: Cedars-Sinai Medical Center Los Angeles, California, United States

View Trial Details

Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Conditions: Hematologic Diseases, Hematologic Malignancy, Hematologic Neoplasms, +13 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

NCT05245656

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Samsung Medical Center Seoul, Gangnam-Gu, South Korea

View Trial Details

Recruiting

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details